Full Press Release Details
TONIX PHARMACEUTICALS HOLDING CORP. 8-K
Pharmaceuticals Announces Proposed Public Offering
N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"),
a fully-integrated biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock (or pre-funded
warrants in lieu thereof). All of the securities to be sold in the offering are to be offered by Tonix. The offering is subject to market
conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the
Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including the preparation
of the new drug application relating to its Tonmya product candidate in patients with fibromyalgia, and the satisfaction of any
portion of its existing indebtedness.
James Securities, Inc. is the sole placement agent for the offering.
offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-266982) previously filed with
the U.S. Securities and Exchange Commission (the "SEC"). The offering will be made only by means of a prospectus supplement
and accompanying prospectus. The preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering
will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Electronic copies of the preliminary
prospectus supplement may be obtained, when available, from Dawson James Securities, Inc., 101 North Federal Highway, Suite 600, Boca
Raton, FL 33432 or by telephone at (561) 391-5555, or by email at investmentbanking@dawsonjames.com. Before investing in this offering,
interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that
Tonix has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which
provide more information about Tonix and such offering.
press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.
Pharmaceuticals Holding Corp.*
is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent
human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. Tonix's
priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya1, a product candidate
for which two statistically significant Phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL is also being
developed to treat acute stress reaction as well as fibromyalgia-type Long COVID. Tonix's CNS portfolio includes TNX-1300 (cocaine
esterase), a biologic designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix's immunology development
portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized
monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment
of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines,
our commercial subsidiary, markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray)
10 mg for the treatment of acute migraine with or without aura in adults.
product development candidates are investigational new drugs or biologics and have not been approved for any indication.
is conditionally accepted by the U.S. Food and Drug Administration (FDA) as the tradename for TNX-102 SL for the management of fibromyalgia.
Tonmya has not been approved for any indication.
SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.
press release and further information about Tonix can be found at www.tonixpharma.com.
statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast,"
"estimate," "expect," and "intend," among others. These forward-looking statements are based on Tonix's
current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the
failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market
any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional
financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited
research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development,
there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an
obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on
Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the "SEC") on April
1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly
qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.